Connect with us

News

NHS makes fresh uptake appeal as five million women not up to date with cervical screening

Published

on

Women are being urged to come forward for cervical screening as new figures show more than five million are not up to date with their routine check-ups.

The NHS invites women for screening every three to five years depending on their age, or more frequently if the high-risk human papillomavirus (HPV) is detected, with the programme saving thousands of lives annually.

The NHS Cervical Screening Programme, England 2023-2024 annual report found that 68.8 per cent of 25 to 64-year-olds were screened within the recommended period of time, compared to 68.7 per cent the previous year.

Coverage was higher for 50 to 64-year-olds at 74.3 per cent compared with 25 to 49-year-olds at 66.1 per cent.

In 2023-24, everyone who was due a test – a total of 5.12 million individuals aged 25 to 64 in England – was invited to book an appointment, and 3.25 million were tested during the year.

Last year, the NHS pledged to eliminate cervical cancer by 2040 by making it as easy as possible for people to get the lifesaving HPV vaccination and encouraging more women and people with a cervix to come forward for their cervical screening.

Earlier this month, the NHS set out reforms to fully digitise screening – by announcing the rollout of a new “ping and book” service that will send alerts to phones to remind women they are due or overdue an appointment.

The plans will begin with invitations for breast screening being sent directly through the NHS App, and be expanded to include cervical screening in Spring 2025.

NHS cervical screening helps prevent cervical cancer by using a highly effective test to check for HPV, which is found in over 99 per cent of all cervical cancers and which may cause abnormal cells to develop in the cervix. These abnormal cells can, over time, turn into cancer if left untreated.

Women who are due a cervical screening appointment will receive invitation letters by post when it’s time to book. Appointments can be booked through GP practices and some sexual health clinics also offer the service. A

nyone who has previously received an invitation and been unable to attend shouldn’t wait for another invitation – you can still book a cervical screening appointment even if invited weeks, months or years ago.

Sue Mann, NHS England’s National Clinical Director for Women’s Health, said: “We have set ourselves an ambitious target of eliminating cervical cancer by 2040 – a commitment shared by only a few countries worldwide.

“In order to achieve this, we are working hard to ensure that everyone who’s eligible has access to HPV vaccination and cervical screening appointments, and that they are suitably informed on how to book and what to expect at an appointment.

“If we are to make real inroads into eradicating cervical cancer, it’s essential that everyone who is invited for screening comes forward when invited.

“If you have previously missed your appointment, do not hesitate to reach out to your GP practice or sexual health clinic to schedule a new one. Taking this proactive step could potentially save your life.”

Sophia Lowes, Senior Health Information Manager at Cancer Research UK, said: “Cervical screening saves thousands of lives every year in the UK.

“It’s for people without symptoms and helps to prevent cervical cancer from developing in the first place.

“Cancer Research UK encourages everyone who receives an invitation to take part.

“Some people may have found cervical screening uncomfortable in the past or have experienced other barriers to taking part.

“But there are things you can ask for to help you feel more comfortable, such as asking for a nurse of a specific gender or asking for a smaller speculum – the tool that nurses use to look at your cervix.

“You can also ask for a longer appointment so you can talk through any concerns with the nurse on what adjustments you might need.

“On top of this, the NHS in England is taking steps to make it easier to take part in cervical screening, such as letting you book your appointment through the NHS App.

“In the future, innovations like HPV self-sample kits, which allow people to collect a sample for testing themselves, could help more people take part.

“We’re looking forward to seeing the impact these new initiatives could have.”

England is among the first countries in the world to set the elimination ambition for cervical cancer within the next two decades.

The World Health Organization considers cervical cancer to be eliminated as a public health problem when there is an incidence rate lower than four per 100,000 women.

Diagnosis

Lung cancer drug shows breast cancer potential

Published

on

Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.

PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.

Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.

The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.

In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.

Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.

Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.

Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”

John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”

Continue Reading

Insight

Higher nighttime temps linked to increased risk of autism diagnosis in children – study

Published

on

Nighttime temperatures during pregnancy may be linked to a higher chance of an autism diagnosis in children, a recent study suggests.

The research tracked nearly 295,000 mother-child pairs in Southern California from 2001 to 2014 and linked warmer overnight temperatures with higher risk in early and late pregnancy.

Children of mothers exposed to higher than typical nighttime temperatures during weeks one to 10 of pregnancy had a 15 per cent higher risk of an autism diagnosis.

Exposure during weeks 30 to 37 was linked to a 13 per cent higher risk.

 Lead author David Luglio, a post-doctoral fellow at Tulane University, said: “A key takeaway is that we identified specific windows when a mother and her developing child can be most affected by exposures to higher nighttime temperatures.

“This is critical and hopefully can help mothers prepare accordingly.”

The study is described as the first to examine how temperature may affect fetal neurodevelopment, the process by which a baby’s brain and nervous system form during pregnancy.

Extreme temperatures linked to increased risk were classified as above the 90th percentile, meaning 3.6°F hotter than average, and the 99th percentile, 5.6°F above average.

The association held even after researchers accounted for factors such as neighbourhood conditions, vegetation and fine-particle air pollution.

The study could not account for other factors such as access to air conditioning. Researchers did not find the same association with daytime temperatures, potentially because people spend more time away from home during the day.

“Heat waves are becoming more frequent, and people may only think of the dangers of daytime heat exposure,” said Mostafijur Rahman, assistant professor of environmental health sciences at Tulane University.

“These results indicate a strong association between high nighttime temperatures during pregnancy and autism risk in children and show that we need to think about exposure to heat around the clock.”

The study did not examine how higher temperatures at night might affect prenatal development, though Luglio said it is possible that warmer nights disrupt sleep for pregnant mothers.

Previous research has suggested insufficient sleep during pregnancy may be linked to a higher risk of neurocognitive delays in children.

“Extreme heat exposure during pregnancy has been linked to a range of adverse health outcomes, including prenatal neurodevelopment delays and complications with an embryo’s development of a central nervous system,” Luglio said.

“The goal of our study was to specifically explore the link between prenatal heat exposure and autism diagnoses for the first time.”

Continue Reading

Entrepreneur

Kindbody unveils next-gen fertility platform

Published

on

Kindbody has launched a fertility platform integrating AI with clinical care and patient support for employers and health plans.

The platform will enter a pilot with select Kindbody employer clients in 2026, covering over three million lives, ahead of wider availability in 2027.

Building on the company’s clinical model, the platform aims to improve outcomes and cost efficiency across family-building journeys. It connects Kindbody-owned clinics, partner clinics and an integrated clinical app.

The app offers virtual care across conception, pregnancy and reproductive health, extending through the menopause transition.

Launch features include updates in medication management, third-party reproduction, adoption, pregnancy, men’s health and global programme design.

David Stern, chief executive of Kindbody, said: “With our next-generation fertility platform, Kindbody is redefining what comprehensive, intelligent and affordable family-building care looks like for employers, health plans and patients.

“By unifying best-in-class clinical care, AI-driven intelligence and whole-person support, we are making it easier and more cost-effective for more people to build the families they envision.”

Kindbody has expanded access via its national network of IVF centres, including IVIRMA, Inception Fertility and Ivy Fertility.

A new Fertility Medication Portal is designed to streamline authorisations so medicines can be dispensed on time, giving patients visibility from prescription to coverage, pharmacy fulfilment and delivery tracking.

Through KindMan, men’s health education, digital resources and integrated clinical care are expanding, including hormone management programmes.

Services cover andropause (age-related testosterone decline), erectile dysfunction, low testosterone and other male reproductive conditions.

Specialist fertility care includes semen analysis, diagnostic testing, male hormone panels, genetic testing, surgical sperm extraction and sperm cryopreservation.

Launching in the second quarter, a pregnancy support app will act as a digital companion for expecting and new parents, with resources, interactive tools and clinical assessments to identify social drivers of health and mental health needs during pregnancy and beyond.

Kindbody’s physician-led menopause programme provides consultations with board-certified obstetricians and gynaecologists to diagnose, treat and manage menopausal symptoms, including hormone replacement therapy where appropriate, with support from nutritionists, mental health therapists and pelvic floor specialists.

AI and analytics will be embedded across the care journey. An AI care navigator will guide employees from benefit activation through intake, triage and scheduling.

Tools will track benefits and treatment plans, showing coverage and expected out-of-pocket costs at each step.

AI-supported scribing will assist clinicians with documentation, and a predictor tool will estimate a patient’s likelihood of having a baby across different treatment paths.

In 2027, Kindbody plans a savings model for eligible large employers that it says will guarantee lower total fertility spend while improving clinical efficiency and patient experience.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.